A'Lydia M. Gibbs filed a lawsuit Gibbs v. Astrazeneca Pharmaceuticals LP et al, Case No. N17C-03-1695, Superior Court of the State of Delaware on Mar. 31, 2017, claiming that she suffered kidney-related injuries due to her ingestion of the over-the-counter PPIs Nexium, Prilosec and Prevacid.
A PPI reduces acid production by blocking the enzyme in the wall of the stomach that produces acid that can cause ulcers in the stomach, esophagus and duodenum.
In her PPI lawsuit, Gibbs alleges that the defendants, which include Astrazeneca, Procter & Gamble and Takeda Pharmaceuticals, "actively concealed" the "true and significant risks" associated with PPI use, which research has shown can contribute to chronic kidney disease (CKD) and end-stage renal disease (ESRD).
A study published JAMA Internal Medicine in February 2016 found that the use of PPIs was associated with a higher risk of chronic kidney disease.
READ MORE PROTON PUMP INHIBITOR LEGAL NEWS
The PPI lawsuit contends that the makers of Nexium, Prilosec and Prevacid failed to warn of adverse drug reactions, which they had reason to know can be caused by or are associated with the use of PPIs.
"Defendants concealed and continue to conceal their knowledge that PPIs can cause kidney injuries from Plaintiff, other consumers, and the medical community," according to the complaint. "Specifically, defendants have failed to adequately inform consumers and the prescribing medical community against the serious risks associated with PPIs and have completely failed to warn against the risk of CKD and ESRD."
According to the lawsuit, Gibbs will allegedly require lifelong medical treatment, monitoring and/or medications for her injuries.